Merck & Co. Stock Gains on Pipeline Update and Guidance Upgrades

Merck & Co.'s stock is trading at around $144.71 on the New York Stock Exchange as of September 14, 2026.

The company's recent pipeline update and guidance upgrades have contributed to its valuation, with management stating that its transformation is underway across oncology, vaccines, and animal health.

At the Morgan Stanley 24th Annual Global Healthcare Conference, Merck reiterated and sharpened its long-term revenue ambition, saying its earlier guidance for more than $70 billion in recent-launch and pipeline revenue by the mid-2030s now looks conservative.

The company's shares have delivered strong returns over the past year, with a 78.78 percent rise year-on-year, substantially ahead of Bristol Myers' 38.30 percent gain over the same period.

However, Merck's management and some analysts highlight risks such as potential slower growth for blockbuster immunotherapy Keytruda from 2027 onward and the need to keep replenishing the pipeline through business development.